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Background: Pharmacovigilance (PV) as a means of ensuring drug safety is an essential
component of the process ensuring that the risk of drug use does not outweigh the benefit.
Pharmacists are valuable in collecting PV information, but not many studies explored the
knowledge, perceptions and practices of both community and hospital pharmacists to-
wards the practice of PV.
Objectives: The aim of the study was to explore the knowledge, perceptions and practise of
PV amongst the pharmacists in a selected district of North West Province, South Africa.
Method: A cross sectional study was conducted amongst pharmacists in a selected district
of the North West province, using a pre-tested questionnaire. Descriptive statistics were
used to analyse the results including ANOVA testing.
Results: One hundred and two pharmacists (68.9%) completed the questionnaire. Although
familiar with the concept of PV, pharmacists knowledge scores were low. Pharmacists
agreed that PV is a useful tool, but perceived the PV authorities to be distant and remote.
Although more than 90% indicated that all adverse drug reactions should be reported, only
44.1% indicated that they have reported adverse drug reactions (ADRs). Only 6.7% of
pharmacists were satisfied with feedback received from authorities after reporting an ADR.
Barriers were cited that prevented them from reporting ADRs. Over 80% indicated they
would participate in further PV training.
Conclusion: The majority of pharmacists are familiar with the concept of PV, but less than
half reported any ADR. They are willing to participate in PV processes but are unsure what
their exact role playing should be. More than half indicated that they would like to see
improvements to the current PV system in South Africa. The majority are prepared to
undergo further education to improve their PV knowledge.
© 2016 The Authors. Publishing services by Elsevier B.V. on behalf of Johannesburg Uni-
versity. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/)..C. Joubert), naidoopj@ukzn.ac.za (P. Naidoo).
sburg University.
rvices by Elsevier B.V. on behalf of Johannesburg University. This is an open access article
tivecommons.org/licenses/by-nc-nd/4.0/).
h e a l t h s a g e s ondh e i d 2 1 ( 2 0 1 6 ) 2 3 8e2 4 4 2391. IntroductionAdverse drug reactions (ADRs) are a significant cause of
morbidity and mortality worldwide (WHO, 2002). It is an
important and sometimes avoidable cause for hospital ad-
missions, adding to the social and financial burden of
healthcare (Patel, Bell, & Molokhia, 2007). In Europe ADRs are
responsible for 5% of all hospital admissions causing on
average 1.91 extra hospital days (Montanari-Vergallo, 2013). In
the USA, ADRs are among the top 10 leading causes of death
(Montanari-Vergallo, 2013). Over a 10 year period (1999e2009)
the number of hospital admissions associated with ADRs in
England increased by 76.8% (Wu et al., 2010).
In a South African study, hospital admissions because of
ADRs were found to be 6.3% and 41% of these developed while
the patients were in hospital. Many of the ADRs (46.2%) were
considered preventable. The median hospital stay of patients
because of ADRs was 5 days, placing a substantial additional
burden on the healthcare system (Mehta et al., 2008).
Managing ADRs are done by applying the science and
principles of the discipline of pharmacovigilance (PV). The
World Health Organisation (WHO) initially defined PV as the
science and activities relating to the detection, assessment,
understanding and prevention of adverse effects or any other
possible drug related problem (WHO, 2004). The definition has
since been extended to include all aspects of medicine
development, manufacturing, registration, warehousing, lo-
gistics, prescribing, dispensing, use and the destruction of
expired medicine stock e spanning the complete product life
cycle. Many countries, notably in Europe and the USA, for-
malised PV risk-benefit legislation to be enforced by their
medicine regulatory authorities (Montanari-Vergallo, 2013).
All effects and interactions of medicine, including ADRs,
cannot be detected during pre-marketing clinical trials
because of the minimal number of patient exposure, lack of
long term use, existence of co-morbid conditions, diversity of
patient populations and concomitant use of a wide variety of
other medications, herbs and foods (Smith, Wertheimer, &
Fincham, 2013). Post-marketing surveillance and continuous
PV processes are therefore essential to monitor effects of
medicine, ensuring the safe use of medicine.2. Key concepts
2.1. Spontaneous reporting
This is reporting an ADR by any healthcare professional,
including patients, relatives and others,“spontaneously” as it
was observed. A spontaneous report is an unsolicited
communication by healthcare professionals or consumers
that describes one or more ADR in a patient who was given
one or more medicinal product. Spontaneous reporting, also
called individual case safety reports (ICSR), is the most com-
monmethod ofmedicine surveillanceworldwide. ICSRs play a
major role in the identification of signals of risk once a
medication is used. It may also be possible to recognise a new
risk factor for a product or as a sub-group of patients at
particular risk (WHO, 2009).The main limitation of spontaneous reporting is under-
reporting of ADRs. As in most countries, spontaneous report-
ing is voluntary and unpaid without specific target goals.
However, the main purpose is not the quantification of the
frequency of adverse reactions, but the identification of signals
(WHO, 2009). Studies indicated that various barriers exist that
hinder persons to report ADRs (Zollezzi & Parsotam, 2005).
2.2. Cohort event monitoring (CEM)
This is a prospective, observational, cohort study of adverse
events associated with one or more medicines. It is normally
recommended that a cohort of 10,000 patients be enrolled
giving a 95% chance of identifying a specific event that has an
incidence of CI:3000. For a meaningful assessment, at least
three events need to be identified, hence the higher objective
to include 10,000 patients (WHO, 2009). Where available, CEM
is often combined with Prescription Event Monitoring (PEM),
for example the Intensive Medicines Monitoring Programme
in New Zealand and the Prescription Event Monitoring in the
UK and Japan. PEM is a system where the pharmacists, after
dispensing the medication of interest, reports the patient
details to a PV centre who then contacts the patient or
physician regarding the patient-experience with themedicine
(Pal, Duncombe, Falzon, & Olsson, 2013).
2.3. Targeted spontaneous reporting (TSR)
This is where all the patients are monitored when and where
the medicine of interest is dispensed. For instance, where
patients receive treatment changes for drug-resistant TB or
switching from first-line to second-line antiretroviral therapy,
the pharmacists is sensitised to be cognitive for the occur-
rences of ADRs. The advantage of TSR is that an ADR can be
identified sooner and the patient is referred for treatment
immediately (Pal et al., 2013).
Reporting by consumers have also been allowed by many
countries.3. Purpose, aims and objectives
3.1. Importance of pharmacists
Pharmacists have a central role in drug safety by contributing
to the prevention, identification, documentation, and report-
ing of ADRs (Zollezzi & Parsotam, 2005).
Pharmacists do not have the same clinical experience as
physicians but are capable of reporting ADRs on their own.
Indeed, over a 10 year period, pharmacists reported 31% of all
ADRs in a Portuguese study (Marques, Ribeiro-Vaz, Costa
Pereira, & Polonia, 2013). In many other countries, especially
the Netherlands, pharmacists report a substantial number of
ADRs (Van Grootheest, 2003).
Communicating effective risk information back to health-
care workers is the result of a successful PV process. A major
step in the prevention of ADRs is to ensure that all healthcare
workers are informed about the change in the risk-benefit
profile of the medicine (Van Grootheest, 2003).
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keep the report forms, have resources to send completed forms
to the nearest PV centre provide a receiving postal address for
any information, newsletter or “Dear Dr letter” regarding the
safety of medicine. This administrative role is vital in keeping
the PV process functioning (Van Grootheest, 2003).
South Africa has a very high HIV and Tuberculosis infec-
tion rate. In 2007, with less than 1% of the world's population,
South Africa had 17% of the global HIV burden and one of the
world's worst tuberculosis epidemics, including drug-
resistance tuberculosis. Malaria infections are also a cause
for alarm (Karim, Churchyard, Karim,& Lawn, 2009). Although
there are chemical agents to combat these infections, the
therapy is more often disrupted by ADRs causing therapy
changes and diminished patient compliance (Chowers et al.,
2009).
However, to meet these health challenges, pharmacists
can be deployed to assist in monitoring the safe and effective
use of available medicine, which certainly includes the man-
agement of ADRs. Pharmacists are valuable in collecting PV
information, but not many studies explored the knowledge,
perceptions and practices of both community and hospital
pharmacists towards the practice of PV.
Hence the aim of this studywas to examine the knowledge,
perceptions and practices of PV among community and hos-
pital pharmacists in a selected district of NorthWest Province,
South Africa.4. Materials and methods
4.1. Study design, population
A descriptive cross sectional study was conducted over a
period of 4 months from March to June 2013. The South Afri-
can Pharmacy Council database and SA Telkom telephone
directory was used to access contact details of all community
and hospital pharmacists practising in the Kenneth Kaunda
district of the NorthWest province. A total of 148 pharmacists
were identified.
4.2. Instrument
A coded, anonymous questionnaire was developed containing
mostly closed ended questions with the exception of the last
question where pharmacists were invited to describe their PV
experiences or opinions in their own words. Two sets of
double negative questions were included to cross check cor-
rect knowledge and attitude questions. The other questions
were grouped under the following headings: Demographics,
Knowledge, Perceptions, Practice and Barriers. An on-line
equivalent of the questionnaire was programmed by the
researcher and hosted @ http://www.pcv.za.org/. In the on-
line questionnaire, 2 questions were added aiming to verify
the respondent as being a pharmacists.
4.3. Ethical consideration
Ethics approval was obtained from the University of KwaZulu-
Natal-ethics number HSS/1285/012M.5. Data collection, capture and analysis
The questionnaire was administered to the pharmacists after
obtaining their consent. Pharmacists were informed of the
purpose, benefits and risks of the study, as well as their right
to withdraw at any stage. There was no interaction between
the participants and the researchers after the procedure had
been explained.
For analysis purposes 4 groups of pharmacists were iden-
tified depending on the place of work namely: Public or Private
Sector, Hospital or Community Pharmacy.
The collected data was entered onto a MS Excel spread
sheet and then analysed using the IBM Statistical Package for
Social Sciences (SPSS) version 21.0 with a p < 0.05 indicating
statistical significance. Frequency tables with bar charts were
used to describe responses to categorical questions while
scores were summarised using mean, standard deviation and
range. ANOVA (analysis of variance) testing was used to
compare mean scores between the four groups of
respondents.6. Results and findings
One hundred and two of the 148 pharmacists completed the
questionnaires, giving a response rate of 68.9%. The reason
why the researcher could not achieve a 100% participation
was refusal by pharmacists to participate or employer refusal
for pharmacists to participate. The other reasons were of a
logistical or unknown nature.
6.1. Demographic collection
The majority (>90) of the respondents graduated from the
local university of North West Province. Almost all pharma-
cists (>95%) were employed full time with 27.5% being self-
employed. Other demographic and professional details of re-
spondents are shown in Table 1.
6.2. Knowledge of pharmacovigilance (6 questions)
The results on the knowledge questions are depicted in Fig. 1.
The knowledge scores ranged from 0 to 92% with a mean of
42% and a standard deviation of 22%. There was a large range
in knowledge score and the average level of knowledge was
low. The highest knowledge score was in the private com-
munity pharmacies, followed by the public hospital pharma-
cies and lowest in the private hospital pharmacies. However
the difference in knowledge between the groups was not
statistically significant (p ¼ 0.199).
6.3. Attitude and perceptions (11 questions)
Responses to individual perception questions are shown
below in Table 2. Although PV is regarded as a useful tool,
reporting pathways to the national PV centres are virtual and
remote (Medicine Control Council 61.8%, NADEMC 55.9%).
Most pharmacists take responsibility for the risk associ-
ated with the medicine they dispense (79.4%) and indicated
Table 1 e Demographic and professional information of
participants.
Category N N%
Participants 102 100.00%
Gender Male 39 38.20%
Female 63 61.80%
Age group 20e30 30 29.40%
31e40 29 28.40%
41e50 22 21.60%
51e60 9 8.80%
61e70 12 11.80%
Sector Private 49 48.00%
Public 53 52.00%
Pharmacy type Community 44 43.10%
Hospital 58 56.90%
Qualification B Pharm 81 79.41%
Post Graduate 21 20.59%
Management Pharmacists 80 78.40%
Responsible
Pharmacists
22 21.60%
Table 2 e Responses to questions on attitude and
perceptions.
Question N N%
Participants 102 100.00%
PV unrealistic tool Yes 9 8.8%
No 81 79.4%
Unfamiliar 6 5.9%
Not answered 6 5.90%
MCC is remote Yes 63 61.80%
No 27 26.5%
Unfamiliar 5 4.9%
Not answered 7 6.9%
NADEMC is remote Yes 57 55.9%
No 22 21.6%
Unfamiliar 13 12.7%
Not answered 10 9.8%
Medicine risk Yes 82 80.4%
No 12 11.8%
Unfamiliar 1 1.0%
Not answered 7 6.9%
Not responsible Yes 7 6.9%
No 92 90.2%
Unfamiliar 0 0.0%
Not answered 3 2.9%
Do not report on
ADR if unlisted
Yes 10 9.8%
No 88 86.3%
Unfamiliar 0 0.0%
Not answered 4 3.9%
Do not report on
older medicine
Yes 6 5.9%
No 92 90.2%
Unfamiliar 1 1.0%
Not answered 3 2.9%
Do not report on
rare ADRs
Yes 6 5.9%
No 93 91.2%
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cine 90.2%, new medicine 91.2%).
Most pharmacists receive PV notifications by manufac-
tures (73.5%) and 60.8% indicated that sufficient information is
supplied to them.
6.4. Practices and activities (10 questions)
Responses to individual practice and activity questions are
listed in Table 3. Forty Five (44.1%) respondents indicated that
they did report an ADR. This correlates with the number ofFig. 1 e Percentage of correct answers for knowledge
questions. In the above figure, each of the variables used
corresponded to the following question in the surveyed
questionnaire. 1) Familiarity e “Are you familiar with the
term Pharmacovigilance (PV) ?”. 2) Definition e “Please
define Pharmacovigilance”? 3) Role players e “Who should
participate in Pharmacovigilance activities?”. 4) PV Unit e
“Where is the seat of the National South African
Pharmacovigilance unit?”. 5) Nademc e “What does
Nademc stand for? (National Adverse Drug Event
Monitoring Centre)”. 6) Nademc City e “In what city does
Nademc operate from?”.
Unfamiliar 0 0.0%
Not answered 3 2.9%
Receive ‘Dear Dr’ letters Yes 75 73.5%
No 24 23.50%
Unfamiliar 0 0.0%
Not answered 3 2.9%
Letter info is of
good quality
Yes 62 60.8%
No 30 29.4%
Unfamiliar 1 1.0%
Not answered 9 8.8%
Letter info is clear Yes 82 80.4%
No 11 10.8%
Unfamiliar 0 0.0%
Not answered 9 8.8%
PV: Pharmacovigilance.
MCC: Medicines Control Council of South Africa.
NADEMC: National Adverse Drug Event Monitoring Centre.
ADR: Adverse drug reaction.respondents that entered a positive value in the “Report time
after ADR” question.
The response of 36.3% (37/102) to the question “Number of
ADRs reported” (any number of reports) gave a mean of 41.5%
report activity across all the ADR report questions. On the
question of feedback, the overall score was very low (<20%)
identifying feedback as a problem. Thirty nine of the forty
seven (83%) respondents who managed an ADR, had a suc-
cessful intervention with 17% being unsuccessful. More than
50% of the respondents were not satisfied with the South Af-
rican PV system.
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Responses to the questions on barriers are depicted in Fig. 2.
It can be seen from this graph that 50% found reporting to
be time consuming whilst over 38% and 35% indicated that
they do not know how to report or where to report respec-
tively. A percentage of the respondents (12.75%) did not report
because they felt that the ADR were not of a serious nature.8. Discussion
8.1. Response rate
The response rate of 68.9% was found to be consistent and
comparable to studies done in other countries (Oreagba,Table 3 e Pharmacovigilance practice and activities.
Question N N%
Participants 102 100.00%
Reported an adverse
drug reaction
Yes 45 44.1%
No 56 54.9%
Not answered 1 1.0%
Reported time after
adverse drug reaction
Immediately 19 18.6%
Within days 16 15.7%
Within weeks 5 4.9%
Within months 3 2.9%
Much later 2 2.0%
Not answered 57 55.9%
Number of reports None 62 60.8%
1e10 27 26.5%
10þ 2 2.0%
20e30 1 1.0%
40 1 1.0%
Many 6 5.9%
Not sure 3 2.9%
Received feedback Yes 18 17.6%
No 43 42.2%
Not answered 41 40.2%
Time feedback received Same day 3 2.9%
Days 3 2.9%
Weeks 9 8.8%
Months 1 1.0%
Long time 1 1.0%
Never 1 1.0%
Not answered 84 82.40%
Feedback sufficient Yes 17 16.7%
No 24 23.5%
Not answered 61 59.8%
Managed adverse
drug reaction
Yes 47 46.1%
No 8 7.8%
Not answered 47 46.1%
Successful intervention Yes 39 38.2%
No 8 7.8%
Not answered 55 53.9%
Outcome of adverse
drug reaction
Death 3 2.9%
Disability 3 2.9%
Hospitalisation 5 4.9%
Other 7 6.9%
Not answered 84 82.40%
Pharmacovigilance
system in SA
Yes 19 18.6%
No 52 51.0%
Not answered 31 30.4%Ogunleye, & Olayemi, 2011; Toklu & Uysal, 2008; Van
Grootheest, 2003).8.2. Demographics
In this study, age, gender, post-graduate qualification, self-
employment and management role was taken to estimate
experience. However, there was no significant correlation
between pharmacists experience and knowledge score.8.3. Knowledge
Although 62.8% of respondents stated that they are familiar
with the concept of PV only 46.1% selected the correct WHO
definition of PV. This finding supports the observation that
most pharmacists would associate the term PV with “side
effects” of medicine but they lack in depth knowledge of ADR
and the associated PV processes. Other studies have also
found this merging of the terms “side effect” with “adverse
drug reaction” (Amrita & Roomi, 2011).
Only a small percentage of respondents (8.8%) selected the
correct answer that all healthcare workers are role players in
the PV process, a finding supported by another study where
pharmacists appearmisinformed about PV processes (Palaian,
Ibrahim, & Mishra, 2011). It is therefore important to define
and communicate the PV function of pharmacists more
clearly (Palaian et al., 2011).
An interesting finding in this studywas that the knowledge
score for community pharmacists was the highest compared
to the pharmacistsworking in the other sectors. This finding is
not consistent with many other studies done on PV in other
countries where hospital pharmacists knowledge of PV is
better than pharmacists in the other sectors (Prakasam,
Nidamanuri, & Kumar, 2012). However the difference in
knowledge scores within the groupswas not significant in this
study.Fig. 2 e Barriers to reporting ADR.
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Most respondents (79.4%) regarded PV as a valuable tool. This
response is consistent with other studies that found that phar-
macists are very positive about the prospect of workingwith PV
cases (Granas, Buajordet, Stenberg-Nilsen, Harg, & Horn, 2007).
All respondents expressed the opinion that they would like
to seemore communication between them and the PV centres.
These institutions seem to be unacceptable for pharmacists,
therefore pharmacists tend to regard them as virtual and
remote with little or no personal contact. A high percentage of
the respondents expressed low satisfaction with the SA PV
system. This seems to be the case in many African countries
where a functional PV system is underdeveloped or absent due
to pressing other priorities. Where present in an African
country, the PV activities are mostly driven by manual mech-
anisms of reporting (Kiguba, Karamagi, Waako, & Bird, 2013).
8.5. Practice and activities
Forty five (44.1%) respondents indicated that they have re-
ported an ADR. Compared to other studies, this is a relative
high rate of reporting (Marques et al., 2013; Prakasam et al.,
2012). In the South African context there is a greater patient
exposure to antiretroviral and anti-malaria products that have
a range of toxic effects and are prone to ADRs (Chowers et al.,
2009; Karim et al., 2009). Thismay contribute to the high report
rate seen in this study.
It was clear that there was a gap in managing feedback to
the reporters. Even though 35 pharmacists reported within
days after an ADR was detected, only 6 respondents stated
that they got feedbackwithin days. This clearly poses a barrier
to pharmacists wanting to participate in PV activities. This
minimal feedback is a barrier cited in other PV studies (Van
Grootheest, 2003; Zollezzi & Parsotam, 2005).
8.6. Barriers
Some of the barriers cited in this study are consistent with
barriers found in similar studies, these include how to report,
where to report, where to obtain a form, the reporting form
not user friendly and poor feedback, etc (Oreagba et al., 2011;
Toklu & Uysal, 2008; Zollezzi & Parsotam, 2005).
Though knowledge was not surveyed as a barrier, a study
done in the Netherlands amongst community sector phar-
macists found that themost frequently reported barrier to not
reporting was the assumption that the ADR was known or the
uncertainty about the causal relationship between the ADR
and a medicine (predisposing factor: knowledge) (Irujo,
Figueiras, Hernandez-Dı´az & Lasheras, 2007; Van Grootheest,
2003). Poor system wide knowledge about the PV processes
could have been a major factor in shaping the answers ob-
tained in this study. The pharmacists (>80%) however indi-
cated their willingness to participate in further PV education.9. Limitations of the study
The small sample size (n ¼ 148) makes the study not repre-
sentative of all pharmacists in South Africa (n > 12,000) butbarely represents the opinion of 1.1%. Because most re-
spondents (>90%) studied at the local university of the North
West Province, the answers might be influenced by the past
curriculum of this institution. A question about previous PV
training could have been useful to asses answers given by
already trained pharmacists and compared it to answers from
pharmacists never trained in PV.When answers to knowledge
questions are available on the Internet, like in this study, the
respondents could have looked up the answer by a variety of
means (smart phone, computers, other connected devices)
and therefore these questions could be biased by false positive
results. It would be advisable for researchers to mitigate this
fact in future research.10. Conclusion
It can be concluded that the knowledge scores of pharma-
cists and their reporting of ADRs are not optimal. The
pharmacist expressed their dissatisfaction of the current PV
system in South Africa. It therefore stands to reason that
the system needs to be strengthened. The pharmacists are
willing to participate in PV processes and are prepared to
undergo further education and training to improve their PV
knowledge and activities. Barriers to participation of phar-
macists in PV activities do exist that will have to be
addressed.11. Recommendation for future research
The authors recommend a similar study with a larger sample
size to be conducted amongst pharmacists, doctors and
nurses in South Africa.
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